WO2003059880A1 - Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant - Google Patents

Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant Download PDF

Info

Publication number
WO2003059880A1
WO2003059880A1 PCT/JP2003/000136 JP0300136W WO03059880A1 WO 2003059880 A1 WO2003059880 A1 WO 2003059880A1 JP 0300136 W JP0300136 W JP 0300136W WO 03059880 A1 WO03059880 A1 WO 03059880A1
Authority
WO
WIPO (PCT)
Prior art keywords
derivative
composition containing
phosphonic acid
medicinal composition
amino alcohol
Prior art date
Application number
PCT/JP2003/000136
Other languages
English (en)
French (fr)
Inventor
Takahide Nishi
Takaichi Shimozato
Futoshi Nara
Shojiro Miyazaki
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03701048A priority Critical patent/EP1471054B1/en
Priority to KR1020047010719A priority patent/KR100836547B1/ko
Priority to NZ533994A priority patent/NZ533994A/xx
Priority to CA2473461A priority patent/CA2473461C/en
Priority to DE60328161T priority patent/DE60328161D1/de
Priority to IL16287403A priority patent/IL162874A0/xx
Priority to BR0306811-0A priority patent/BR0306811A/pt
Priority to DK03701048T priority patent/DK1471054T3/da
Priority to AT03701048T priority patent/ATE435202T1/de
Priority to MXPA04006709A priority patent/MXPA04006709A/es
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Priority to SI200331668T priority patent/SI1471054T1/sl
Priority to AU2003202495A priority patent/AU2003202495B2/en
Publication of WO2003059880A1 publication Critical patent/WO2003059880A1/ja
Priority to US10/889,657 priority patent/US7199150B2/en
Priority to ZA2004/06333A priority patent/ZA200406333B/en
Priority to NO20043319A priority patent/NO329134B1/no
Priority to HK04109418.1A priority patent/HK1066532A1/xx
Priority to US11/636,776 priority patent/US20070105933A1/en
Priority to US11/651,205 priority patent/US7638551B2/en
Priority to US12/460,884 priority patent/US8067396B2/en
Priority to US12/583,001 priority patent/US8101650B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
PCT/JP2003/000136 2002-01-11 2003-01-09 Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant WO2003059880A1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SI200331668T SI1471054T1 (sl) 2002-01-11 2003-01-09 Amino alkoholni derivati ali derivati fosfoniäśne kisline in medicinski sestavki, ki vsebujejo le-te
KR1020047010719A KR100836547B1 (ko) 2002-01-11 2003-01-09 아미노 알코올 유도체 또는 포스폰산 유도체 및 이들을함유하는 의약 조성물
CA2473461A CA2473461C (en) 2002-01-11 2003-01-09 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
DE60328161T DE60328161D1 (de) 2002-01-11 2003-01-09 Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
IL16287403A IL162874A0 (en) 2002-01-11 2003-01-09 Amino alcohol and phosphonic acid derivatives and pharmaceutical compositions containing the same
BR0306811-0A BR0306811A (pt) 2002-01-11 2003-01-09 Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
DK03701048T DK1471054T3 (da) 2002-01-11 2003-01-09 Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
AU2003202495A AU2003202495B2 (en) 2002-01-11 2003-01-09 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
MXPA04006709A MXPA04006709A (es) 2002-01-11 2003-01-09 Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen.
EP03701048A EP1471054B1 (en) 2002-01-11 2003-01-09 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
NZ533994A NZ533994A (en) 2002-01-11 2003-01-09 Amino alcohol derivative or phosphonic acid derivative and medicinal compostion containing these
AT03701048T ATE435202T1 (de) 2002-01-11 2003-01-09 Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
US10/889,657 US7199150B2 (en) 2002-01-11 2004-07-12 Amino alcohol compounds
ZA2004/06333A ZA200406333B (en) 2002-01-11 2004-08-10 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
NO20043319A NO329134B1 (no) 2002-01-11 2004-08-10 Aminoalkoholderivater eller fosfonsyrederivater og farmasoytiske preparater som inneholder disse og som kan anvendes ved profylakse eller behandling av autoimmunsykdommer
HK04109418.1A HK1066532A1 (en) 2002-01-11 2004-11-30 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
US11/636,776 US20070105933A1 (en) 2002-01-11 2006-12-11 Amino alcohol compounds
US11/651,205 US7638551B2 (en) 2002-01-11 2007-01-09 Amino alcohol compounds or phosphonic acid derivatives thereof
US12/460,884 US8067396B2 (en) 2002-01-11 2009-07-24 Amino alcohol compounds or phosphonic acid derivatives thereof
US12/583,001 US8101650B2 (en) 2002-01-11 2009-08-12 Method for treating a immunology-related disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002004484 2002-01-11
JP2002-004484 2002-01-11
JP2002004456 2002-01-11
JP2002-004456 2002-01-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/889,657 Continuation-In-Part US7199150B2 (en) 2002-01-11 2004-07-12 Amino alcohol compounds

Publications (1)

Publication Number Publication Date
WO2003059880A1 true WO2003059880A1 (fr) 2003-07-24

Family

ID=26625490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/000136 WO2003059880A1 (fr) 2002-01-11 2003-01-09 Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant

Country Status (26)

Country Link
US (5) US7199150B2 (ja)
EP (1) EP1471054B1 (ja)
JP (1) JP4270541B2 (ja)
KR (2) KR20080035702A (ja)
CN (1) CN100406437C (ja)
AT (1) ATE435202T1 (ja)
AU (1) AU2003202495B2 (ja)
BR (1) BR0306811A (ja)
CA (1) CA2473461C (ja)
CO (1) CO5640126A2 (ja)
CY (1) CY1109457T1 (ja)
DE (1) DE60328161D1 (ja)
DK (1) DK1471054T3 (ja)
ES (1) ES2327825T3 (ja)
HK (1) HK1066532A1 (ja)
IL (1) IL162874A0 (ja)
MX (1) MXPA04006709A (ja)
NO (1) NO329134B1 (ja)
NZ (1) NZ533994A (ja)
PL (1) PL211954B1 (ja)
PT (1) PT1471054E (ja)
RU (1) RU2330839C2 (ja)
SI (1) SI1471054T1 (ja)
TW (1) TWI283574B (ja)
WO (1) WO2003059880A1 (ja)
ZA (1) ZA200406333B (ja)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005383A1 (ja) * 2003-07-11 2005-01-20 Sankyo Company, Limited アミノアルコール化合物
WO2005030848A1 (en) * 2003-09-19 2005-04-07 Dow Global Technologies Inc. Multifunctional monomers and polyarylene compositions therefrom
WO2006137509A1 (ja) * 2005-06-24 2006-12-28 Daiichi Sankyo Company, Limited Ｐｐａｒ調節剤を含有する医薬組成物
WO2008016133A1 (fr) 2006-08-04 2008-02-07 Daiichi Sankyo Company, Limited Enzyme de phosphorylation d'un médicament
WO2008146691A1 (ja) 2007-05-25 2008-12-04 Daiichi Sankyo Company, Limited 肝炎の予防又は治療のための医薬組成物
US7560477B2 (en) 2002-07-30 2009-07-14 University Of Virginia Patent Foundation Compounds active in sphingosine 1-phosphate signaling
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US7754703B2 (en) 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
US7786173B2 (en) 2006-11-21 2010-08-31 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
US7910617B2 (en) 2004-02-24 2011-03-22 Sankyo Company, Limited Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
US7915315B2 (en) 2006-11-21 2011-03-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
US7964649B2 (en) 2006-11-21 2011-06-21 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
US8008286B2 (en) 2006-01-27 2011-08-30 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
US8173710B2 (en) 2006-02-09 2012-05-08 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
WO2012073991A1 (ja) 2010-12-02 2012-06-07 第一三共株式会社 ピロール誘導体及びその製造方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1471054T1 (sl) * 2002-01-11 2009-12-31 Daiichi Sankyo Co Ltd Amino alkoholni derivati ali derivati fosfoniäśne kisline in medicinski sestavki, ki vsebujejo le-te
JP4771511B2 (ja) * 2003-07-08 2011-09-14 第一三共株式会社 アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物
GB0302094D0 (en) * 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
DK1772145T3 (da) * 2004-07-16 2011-05-30 Kyorin Seiyaku Kk Fremgangsmåde til effektiv anvendelse af medicin og fremgangsmåde til forebyggelse af bivirkninger
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
JP4919374B2 (ja) * 2004-07-29 2012-04-18 第一三共株式会社 免疫抑制剤としての医薬組成物
PL1806338T3 (pl) * 2004-10-12 2016-07-29 Kyorin Seiyaku Kk Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenyio]etylo]-1,3-propanodioiu i jego hydratów oraz produkty pośrednie w ich wytwarzaniu
BRPI0516173A (pt) 2004-10-28 2008-08-26 Sankyo Co derivado de oxazolidina 4,4-substituìdo opticamente ativo, e, procedimento para a preparação de um composto
JP5024851B2 (ja) * 2004-10-28 2012-09-12 第一三共株式会社 光学活性４，４−二置換オキサゾリジン誘導体とその製造方法
KR101297302B1 (ko) * 2005-10-07 2013-08-19 교린 세이야꾸 가부시키 가이샤 2-아미노-1,3-프로판디올 유도체를 유효성분으로 하는간장질환 치료제 및 간장질환 치료방법
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CN101501049B (zh) * 2006-08-08 2013-04-24 杏林制药株式会社 氨基磷酸酯衍生物以及将它们作为有效成分的s1p受体调节剂
EP2053038B1 (en) * 2006-08-08 2016-10-05 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
US20130190278A1 (en) * 2010-07-29 2013-07-25 Laboratoires Fournier Sa Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases
FR2963238B1 (fr) * 2010-07-29 2012-12-28 Fournier Lab Sa Derives de 15-desoxyspergualine pour le traitement et/ou la prevention des maladies inflammatoires oculaires
US9447078B2 (en) 2012-01-20 2016-09-20 Acucela Inc. Substituted heterocyclic compounds for disease treatment
KR20180093177A (ko) 2017-02-10 2018-08-21 (주)홍익바이오텍 죽염과 다공성 광물을 이용한 개껌 제조방법
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006068A1 (fr) * 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Compose benzenique et son utilisation medicale
WO2002006268A1 (fr) * 2000-07-13 2002-01-24 Sankyo Company, Limited Derives d'alcool amino
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002076995A2 (en) * 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1134687A (en) 1966-04-28 1968-11-27 Beecham Group Ltd Acetylenic compounds
IL36730A0 (en) * 1970-05-28 1971-06-23 Chemagro Corp Phosphonamidothioates,their preparation and their use as herbicides and/or plant growth regulators
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
FR2460919A1 (fr) 1979-07-11 1981-01-30 Prod Synthese Ste Indle Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique
US4363918A (en) * 1979-09-11 1982-12-14 Janssen Pharmaceutica N.V. Method of preparing 1-alkyl-3-carboxy-1H pyrrole-2-acetic acids
US4386090A (en) * 1980-12-22 1983-05-31 Delalande S.A. Nitrogen containing 2,3-dihydro naphthalenes, compositions and use
US4716155A (en) * 1981-12-24 1987-12-29 E. R. Squibb & Sons, Inc. Phosphorus containing compounds and hypotensive use thereof
IT1190793B (it) * 1982-04-27 1988-02-24 Magis Farmaceutici Composti attivi nel trattamento dell'ulcera e sintomi allergici della pelle
US4536601A (en) * 1982-09-28 1985-08-20 Dainippon Pharmaceutical Co., Ltd. Optically active N-substituted phenylalaninols and use thereof
JPS5988467A (ja) 1982-11-09 1984-05-22 Yoshitomi Pharmaceut Ind Ltd フエノキシアミノプロパノ−ル誘導体
DK302185A (da) 1984-07-05 1986-01-06 Rolland Sa A 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling
US4634689A (en) * 1985-10-31 1987-01-06 Schering Corporation Phosphinylalkanoyl imino acids
US4667038A (en) * 1985-12-02 1987-05-19 Syntex (U.S.A.) Inc. Tetrahydroisoquinoline derivatives
US4792568A (en) * 1986-04-14 1988-12-20 Rorer Pharmaceutical Corporation Aryl pyrroles as useful antiallergy compounds
JPS63126897A (ja) * 1986-05-02 1988-05-30 Yoshitomi Pharmaceut Ind Ltd 免疫抑制因子
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
GB8712694D0 (en) * 1987-05-29 1987-07-01 Scras Tetrahydrofurans etc
IL86740A (en) 1987-06-30 1992-11-15 Tanabe Seiyaku Co Thiphene derivatives,their preparation and pharmaceutical compositions containing them
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
CA1334975C (en) * 1987-11-13 1995-03-28 James H. Holms Furan and pyrrole containing lipoxygenase inhibiting compounds
US5039706A (en) * 1987-11-30 1991-08-13 Du Pont Merck Pharmaceutical Company Antiinflammatory PLA2 inhibitors
NZ227365A (en) * 1987-12-18 1990-10-26 Glaxo Group Ltd Aromatic amino ethers and pharmaceutical compositions
US4977171A (en) * 1988-06-09 1990-12-11 Yashima Chemical Industrial Co., Ltd. Oxa- or thia-zoline derivative
EP0436020A4 (en) * 1988-09-14 1992-03-25 Yoshitomi Pharmaceutical Industries, Ltd. Immunosuppressant
US5266599A (en) * 1989-02-20 1993-11-30 Jouveinal S.A. Use of (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine to increase gastric discharge in a subject
US5068247A (en) * 1989-07-07 1991-11-26 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopentanoic acid compounds and their use as immunosuppressants
HU212415B (en) * 1989-08-25 1996-06-28 Egyt Gyogyszervegyeszeti Gyar Process for producing new cyclic oxym derivatives and pharmaceutical compositions containing them as active components
US5234934A (en) * 1989-08-25 1993-08-10 Egis Gyogyszergyar Aminopropanol derivatives, process for their preparation and pharmaceutical compositions comprising the same
FR2655043B1 (fr) * 1989-11-24 1992-02-07 Adir Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5037853A (en) * 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
GB9000644D0 (en) * 1990-01-11 1990-03-14 Erba Carlo Spa New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) * 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5326692B1 (en) * 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5501980A (en) * 1994-05-20 1996-03-26 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators
US5648270A (en) * 1995-02-06 1997-07-15 Molecular Probes, Inc. Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
DE59108123D1 (de) 1990-12-24 1996-10-02 Hoechst Ag Verfahren zur Acylierung von Alkoholen mit einem immobilisierten Pseudomonas-Lipase
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
NL9101623A (nl) * 1991-09-26 1993-04-16 Dsm Nv Werkwijze voor de bereiding van een alcohol.
ATE191345T1 (de) * 1991-12-11 2000-04-15 Yoshitomi Pharmaceutical Arzneimittel zur behandlung von autoimmunerkrankungen
WO1994004491A1 (en) * 1992-08-25 1994-03-03 G.D. Searle & Co. N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
GB9304589D0 (en) * 1993-03-05 1993-04-21 Erba Carlo Spa Biologically active ureido derivatives useful as antimetastic agents
GB9306473D0 (en) * 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
JPH06345728A (ja) 1993-06-11 1994-12-20 Nissan Chem Ind Ltd Ｎ−置換アゾール誘導体の製造方法
US5717605A (en) * 1993-10-14 1998-02-10 Olympus Optical Co., Ltd. Color classification apparatus
US5534980A (en) * 1994-05-31 1996-07-09 Mita Industrial Co., Ltd. Electrophotographic image forming apparatus having a charge removing means
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
ATE279185T1 (de) * 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
DE69709647T2 (de) * 1996-05-20 2002-11-07 Teijin Ltd Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
ATE218537T1 (de) * 1996-07-22 2002-06-15 Novo Nordisk As Verbindungen mit wachstumshormon freisetzenden eigenschaften
US6077954A (en) * 1996-08-01 2000-06-20 Isis Pharmaceuticals, Inc. Substituted heterocyclic compounds
WO1998015278A1 (en) 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
US5891892A (en) * 1996-10-29 1999-04-06 Warner-Lambert Company Small molecule biaryl compounds as inhibitors of endothelin converting enzyme
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US5732218A (en) * 1997-01-02 1998-03-24 Lucent Technologies Inc. Management-data-gathering system for gathering on clients and servers data regarding interactions between the servers, the clients, and users of the clients during real use of a network of clients and servers
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
WO1998045249A1 (fr) 1997-04-04 1998-10-15 Yoshitomi Pharmaceutical Industries, Ltd. Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
WO1999001420A1 (fr) * 1997-07-03 1999-01-14 Taito Co., Ltd. Procede de preparation de derives d'acide 2-aminomalonique, et intermediaires utilises dans ce procede
WO1999011258A1 (en) * 1997-08-28 1999-03-11 Novartis Ag Lymphocyte function antigen-1 antagonists
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
AU744577B2 (en) * 1997-10-14 2002-02-28 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
DE19745904A1 (de) * 1997-10-17 1999-04-22 Hoechst Ag Polymerstabilisierte Metallkolloid-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Katalysatoren für Brennstoffzellen
DE19817459A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
AU6367399A (en) * 1998-11-02 2000-05-22 Welfide Corporation Pyrrolidine compounds and medicinal utilization thereof
EP1129066B1 (en) * 1998-11-11 2005-02-02 Novartis AG Production of 2-amino-2- 2-(4-c 2-20?-alkyl-phenyl)ethyl]propane-1,3-diols
WO2000033836A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation 5-membered heterocycles for the treatment of human diseases involving modulators of selectins
DE69926806D1 (de) * 1998-12-18 2005-09-22 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
US6525069B1 (en) * 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6178821B1 (en) * 1999-01-25 2001-01-30 General Electric Company Vibration sensing device
ES2234564T3 (es) 1999-02-10 2005-07-01 Mitsubishi Pharma Corporation Compuestos de tipo amida y su uso en medicina.
CN1144779C (zh) 1999-03-11 2004-04-07 杭州中美华东制药有限公司 制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
MXPA02001095A (es) 1999-07-30 2002-08-20 Vertex Pharma Derivados de amina ciclicos y aciclicos.
US6458852B1 (en) * 1999-09-23 2002-10-01 G.D. Searle & Co. Use of substituted N, N-bis-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
DE19963174A1 (de) * 1999-12-27 2001-07-12 Gruenenthal Gmbh Substituierte Pyrrol-Mannichbasen
DE60034605T2 (de) 1999-12-31 2007-09-06 Encysive Pharmaceuticals, Inc., Houston Sulfonamide und deren Derivate als Modulatoren der Endothelin-Aktivität
US6803375B1 (en) 2000-01-06 2004-10-12 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
EP1268455A2 (en) * 2000-03-31 2003-01-02 Pfizer Products Inc. Piperazine derivatives
US6964676B1 (en) * 2000-04-14 2005-11-15 Scimed Life Systems, Inc. Stent securement system
BR0110358A (pt) * 2000-04-28 2003-03-05 Hoffmann La Roche P-(sulfonil)-arila e -heteroarilas
CA2413418A1 (en) * 2000-06-21 2001-12-27 Joseph B. Santella Piperidine amides as modulators of chemokine receptor activity
JP2002053575A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd アミノアルコ−ル類
DE10049483A1 (de) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte 1-Aminobutan-3-ol-Derivate
DE10048714A1 (de) * 2000-09-30 2002-04-11 Gruenenthal Gmbh 5-Amino-1-penlen-3-ol-Derivate
BR0207434A (pt) 2001-02-22 2004-07-06 Novartis Ag Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
DK1389137T3 (da) 2001-05-21 2006-10-30 Injet Digital Aerosols Ltd Sammensætninger til lungelægemiddellevering af protein
GB0117921D0 (en) 2001-07-23 2001-09-12 Novartis Ag Organic compounds
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
DE60223699T2 (de) * 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
MXPA04005428A (es) * 2001-12-06 2004-12-06 Elan Pharm Inc Hidroxietilaminas substituidas.
JP2003267974A (ja) 2002-01-11 2003-09-25 Sankyo Co Ltd アミノアルコ−ル誘導体を含有する医薬組成物
SI1471054T1 (sl) * 2002-01-11 2009-12-31 Daiichi Sankyo Co Ltd Amino alkoholni derivati ali derivati fosfoniäśne kisline in medicinski sestavki, ki vsebujejo le-te
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
MXPA04011384A (es) 2002-05-16 2005-02-14 Novartis Ag Uso de agentes de union del receptor edg en cancer.
EP1539674A1 (en) 2002-09-13 2005-06-15 Novartis AG Amino-propanol derivatives
PL375053A1 (en) 2002-09-24 2005-11-14 Novartis Ag Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
KR101182619B1 (ko) * 2004-02-24 2012-09-18 상꾜 가부시키가이샤 아미노 알코올 화합물
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
TWI418350B (zh) 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006068A1 (fr) * 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Compose benzenique et son utilisation medicale
WO2002006268A1 (fr) * 2000-07-13 2002-01-24 Sankyo Company, Limited Derives d'alcool amino
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002076995A2 (en) * 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560477B2 (en) 2002-07-30 2009-07-14 University Of Virginia Patent Foundation Compounds active in sphingosine 1-phosphate signaling
WO2005005383A1 (ja) * 2003-07-11 2005-01-20 Sankyo Company, Limited アミノアルコール化合物
WO2005030848A1 (en) * 2003-09-19 2005-04-07 Dow Global Technologies Inc. Multifunctional monomers and polyarylene compositions therefrom
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US7910617B2 (en) 2004-02-24 2011-03-22 Sankyo Company, Limited Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
US8329676B2 (en) 2005-02-14 2012-12-11 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
US7754703B2 (en) 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
JPWO2006137509A1 (ja) * 2005-06-24 2009-01-22 第一三共株式会社 Ｐｐａｒ調節剤を含有する医薬組成物
CN101242829B (zh) * 2005-06-24 2011-05-18 第一三共株式会社 含有ppar调节剂的药物组合物
WO2006137509A1 (ja) * 2005-06-24 2006-12-28 Daiichi Sankyo Company, Limited Ｐｐａｒ調節剤を含有する医薬組成物
US8008286B2 (en) 2006-01-27 2011-08-30 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
US8173710B2 (en) 2006-02-09 2012-05-08 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
WO2008016133A1 (fr) 2006-08-04 2008-02-07 Daiichi Sankyo Company, Limited Enzyme de phosphorylation d'un médicament
US7786173B2 (en) 2006-11-21 2010-08-31 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
US7915315B2 (en) 2006-11-21 2011-03-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
US7964649B2 (en) 2006-11-21 2011-06-21 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
WO2008146691A1 (ja) 2007-05-25 2008-12-04 Daiichi Sankyo Company, Limited 肝炎の予防又は治療のための医薬組成物
WO2012073991A1 (ja) 2010-12-02 2012-06-07 第一三共株式会社 ピロール誘導体及びその製造方法
US8846943B2 (en) 2010-12-02 2014-09-30 Daiichi Sankyo Company, Limited Pyrrole derivative and process for production thereof
JP5728027B2 (ja) * 2010-12-02 2015-06-03 第一三共株式会社 ピロール誘導体及びその製造方法

Also Published As

Publication number Publication date
US20070105933A1 (en) 2007-05-10
CA2473461C (en) 2011-11-01
JP4270541B2 (ja) 2009-06-03
RU2330839C2 (ru) 2008-08-10
SI1471054T1 (sl) 2009-12-31
ES2327825T3 (es) 2009-11-04
EP1471054A1 (en) 2004-10-27
US20070142335A1 (en) 2007-06-21
CA2473461A1 (en) 2003-07-24
BR0306811A (pt) 2004-10-26
PT1471054E (pt) 2009-09-23
KR20040075068A (ko) 2004-08-26
DK1471054T3 (da) 2009-11-09
AU2003202495A1 (en) 2003-07-30
TWI283574B (en) 2007-07-11
PL370790A1 (en) 2005-05-30
PL211954B1 (pl) 2012-07-31
US7199150B2 (en) 2007-04-03
HK1066532A1 (en) 2005-03-24
NO329134B1 (no) 2010-08-30
CN1630635A (zh) 2005-06-22
US8101650B2 (en) 2012-01-24
AU2003202495B2 (en) 2006-07-20
US20090326038A1 (en) 2009-12-31
US20100035842A1 (en) 2010-02-11
KR20080035702A (ko) 2008-04-23
US20050043386A1 (en) 2005-02-24
CN100406437C (zh) 2008-07-30
KR100836547B1 (ko) 2008-06-10
RU2004121143A (ru) 2006-02-27
CY1109457T1 (el) 2014-08-13
JP2003267950A (ja) 2003-09-25
NZ533994A (en) 2006-10-27
ZA200406333B (en) 2005-12-28
EP1471054A4 (en) 2005-06-08
DE60328161D1 (de) 2009-08-13
IL162874A0 (en) 2005-11-20
ATE435202T1 (de) 2009-07-15
CO5640126A2 (es) 2006-05-31
MXPA04006709A (es) 2004-10-04
TW200302087A (en) 2003-08-01
US8067396B2 (en) 2011-11-29
EP1471054B1 (en) 2009-07-01
NO20043319L (no) 2004-10-05
US7638551B2 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
WO2003059880A1 (fr) Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant
TW330202B (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
HUP0301688A2 (hu) Aminoalkoholszármazékok, eljárás az elżállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1481965A4 (en) AROMATIC AMINO ACID DERIVATIVES AND MEDICAL COMPOSITIONS
EP1782804A4 (en) MEDICINAL COMPOSITION USEFUL AS IMMUNOSUPPRESSOR
ATE407924T1 (de) Stickstoffhaltige, fünfgliedrige ringverbindungen
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
MY134582A (en) New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments
EP0709373A4 (en) NEW PYRROLIDINE DERIVATIVE
EP1741714A4 (en) HETEROCYLIC COMPOUND AND ANTI-MALIGNANT TUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
WO2003035620A1 (fr) Compose bicyclique
TW200637807A (en) Norvaline derivative and method for preparation thereof
EP0516861A4 (en) Pyridonecarboxylic acid derivative
AU1414900A (en) Novel compound, polymer prepared from the compound, and composition comprising the polymer
HUP0203275A2 (hu) 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása
AR044175A1 (es) Compuestos de cefemo
IL181888A0 (en) Aminoalcohol derivatives and pharmaceutical compositions containing the same
ATE204880T1 (de) N-acyldipeptide, und pharmazeutische präparate davon
GB2334032A (en) Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumour agents
DE69429753T2 (de) Anitbiotisch wirksame Cephalosporine und Verfahren zu ihrer Herstellung
TW262467B (ja)
MXPA05010144A (es) Compuestos de pirazol.
CA2335394A1 (en) Aerothricin analogs, their preparation and use
TW200510300A (en) Amino alcohol compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 162874

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 533994

Country of ref document: NZ

Ref document number: 962/KOLNP/2004

Country of ref document: IN

Ref document number: 00962/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004121143

Country of ref document: RU

Ref document number: PA/a/2004/006709

Country of ref document: MX

Ref document number: 1200400640

Country of ref document: VN

Ref document number: 1020047010719

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2473461

Country of ref document: CA

Ref document number: 10889657

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003701048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003202495

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004/06333

Country of ref document: ZA

Ref document number: 200406333

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1-2004-501022

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 20038059258

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003701048

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP